Rosacea, a common facial skin disease, is estimated to affect over 16 million Americans. According to the National Rosacea Society, “Rosacea may develop in many ways and at any age,
A recent study reviewed the use of cosmetic injectables in individuals with skin of color (S0C) with the aim of assessing their uses, effectiveness, and safety. SoC populations are increasingly
Andrew F. Alexis, MD, MPH, was recently honored at the second annual Fleur De Cure event in New York City. This special gathering, organized by the National Psoriasis Foundation and
The U.S. Food and Drug Administration (FDA) has issued a warning to all health care professionals and consumers revealing that counterfeit versions of Botox (botulinum toxin) have been uncovered in
Global biopharmaceutical company, UCB, recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx) for the treatment
The U.S. Food and Drug Administration (FDA) has issued a warning to consumers to not use certain over-the-counter (OTC) pain relief products due to the potential for dangerous health effects.
Johnson & Johnson recently announced the first data from their FRONTIER 2 clinical trial which evaluated JNJ-2113. This is the first and only investigational targeted oral peptide designed to block
A recent study revealed that multispectral imaging could provide promising accuracy when predicting the progression of pediatric morphea. Morphea, also known as localized scleroderma, is described as “an inflammatory, fibrosing
Recent revelations about the presence of benzene in benzoyl peroxide (BPO)-containing acne products have put dermatologists in a challenging position. Patients are understandably concerned about the safety of their acne
In recent breaking news, concerns surrounding benzene contamination have resurfaced, sparking renewed health worries and heightened regulatory scrutiny. Valisure LLC, an independent laboratory facility, has revealed the results of its
JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be
Findings from a recent analysis have revealed that the administration of intravenous ertapenem demonstrates improvement in clinical and inflammatory markers of hidradenitis suppurativa (HS) in addition to improved patient satisfaction.
LiVDerm’s annual South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) Symposium recently concluded after an impactful few days of dermatology education. Healio was on site, providing coverage of
According to a recent study published in the Journal of Immunity, Inflammation, and Disease, combining topical corticosteroids with dupilumab can significantly help alleviate symptoms associated with atopic dermatitis (AD) in
A recent study evaluated the effects of a moisturizer containing 20% urea on patients with keratosis pilaris (KP) and found that it may help to improve the skin’s smoothness and
In a recent press release, Galderma announced that RelabotulinumtoxinA significantly improved glabellar and lateral canthal lines. Data from their Phase III READY-3 clinical trial reveal that a single dose of
According to a recent phase 2a randomized clinical trial, PF-07038124, a topical PDE4 inhibitor, is an effective and well-tolerated treatment for patients with atopic dermatitis (AD) and plaque psoriasis. “Topical
The U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals Incorporated for the treatment of molluscum contagiosum in adults and pediatric patients aged
On December 19, Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes), a topical gel for the treatment of partial thickness wounds
Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved their new drug application for ZORYVE® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
